The Placement. The Placement is expected to consist of a registered direct offering of up to approximately $15 million (the “Subscription Amount”) of the Company’s ADSs and warrants to purchase ADSs at agreed upon pricing with the investors. Aegis will act as placement agent for the Placement subject to, among other matters referred to herein and additional customary conditions, completion of Aegis’s due diligence examination of the Company and its affiliates, listing approval by the Nasdaq Capital Market (the “Exchange”) of the Securities to be issued, and the execution of definitive transaction agreements between the Company and investors in connection with the Placement (the “Transaction Documents”). The actual size of the Placement, the precise number of Securities to be offered by the Company and the offering price will be the subject of continuing negotiations between the Company and investors.
Appears in 1 contract
The Placement. The Placement is expected to consist of a registered direct offering sale of up to approximately $15 15.0 to $20.0 million (the “Subscription Amount”) of the Company’s ADSs and warrants to purchase ADSs at Securities. The pricing of the Placement will be mutually agreed upon pricing with by the investorsCompany and the investors thereto. Aegis will act as placement agent for the Placement subject to, among other matters referred to herein and additional customary conditions, completion of Aegis’s due diligence examination of the Company and its affiliates, listing approval by the Nasdaq Capital Market Stock Exchange (the “Exchange”) of the Securities to be issued, and the execution of definitive transaction agreements documents between the Company and investors in connection with the Placement (the “Transaction Documents”). The actual size of the Placement, the precise number of Securities to be offered by the Company and the offering price will be the subject of continuing negotiations between among the Company Company, Aegis and investors.
Appears in 1 contract
Sources: Placement Agent Agreement (Sunshine Biopharma, Inc)
The Placement. The Placement is expected to consist of a registered direct offering sale of up to approximately $15 10.0 million (the “Subscription Amount”) of the Company’s ADSs and warrants to purchase ADSs at Securities. The pricing of the Placement will be mutually agreed upon pricing with by the investorsCompany and the investors thereto. Aegis will act as placement agent for the Placement subject to, among other matters referred to herein and additional customary conditions, completion of Aegis’s due diligence examination of the Company and its affiliates, listing approval by the Nasdaq Capital Market Stock Exchange (the “Exchange”) of the Securities to be issued, and the execution of definitive transaction agreements documents between the Company and investors in connection with the Placement (the “Transaction Documents”). The actual size of the Placement, the precise number of Securities to be offered by the Company and the offering price will be the subject of continuing negotiations between among the Company Company, Aegis and investors.
Appears in 1 contract
Sources: Placement Agent Agreement (Sunshine Biopharma, Inc)